Schedule 13G ownership disclosure

X4 Pharmaceuticals Inc

Common Stock, par value $0.001 per share · CUSIP: 98420X202

Event date: 2025-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Bain Capital Life Sciences Fund, L.P.

    Shares: 0 · Class: 0%

  • Bain Capital Life Sciences Fund II, L.P.

    Shares: 64,190 · Class: 0.07%

  • BCIP Life Sciences Associates, LP

    Shares: 7,817 · Class: 0.01%

  • BCLS II Investco, LP

    Shares: 758,598 · Class: 0.8%

  • BCLS I Investco, LP

    Shares: 89,633 · Class: 0.09%

  • BCLS II Equity Opportunities, LP

    Shares: 7,047,216 · Class: 7.43%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193125-26-054779
Form type
SCHEDULE 13G/A
Filer
Bain Capital Life Sciences Fund, L.P.
CIK
CIK 1687968
Filed
Feb 17, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub